Biogen Idec, Inc. (Massachusetts)’s Ongoing Dedication to People Living with MS Showcased in Data Presented at the 63rd Annual Meeting of the American Academy of Neurology

WESTON, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) today announced that data highlighting the company’s focus and drive towards addressing the needs of people living with multiple sclerosis (MS) will be presented at the American Academy of Neurology’s (AAN) 63rd Annual Meeting in Honolulu, April 9-16, 2011. Fifty-five company-sponsored platform and poster presentations featuring data focusing on the company’s innovation and research in the treatment and management of the disease will be presented during the Congress. Highlights will include data on Biogen Idec’s currently marketed products, TYSABRI® (natalizumab) and AVONEX® (interferon beta-1a), as well as four late-stage programs: FAMPYRA® (prolonged-release fampridine tablets), the oral disease-modifying therapy BG-12 (dimethyl fumarate), PEGylated interferon beta-1a and daclizumab.
MORE ON THIS TOPIC